Clinical trials: Tenofovir
HIV-1 Infection
Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency…
- Trial name
- NCT04564547
- Testing
- Islatravir, Ulonivirine, BIC/FTC/TAF
- Where
- 23 sites in United States, France and 1 more
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV/AIDS, HIV-1-infection
Simplifying Treatment and Monitoring for HIV (STREAM HIV)
This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in…
- Trial name
- NCT04341779
- Testing
- Point-of-care viral load testing and tenofovir adherence testing
- Where
- South Africa
- Volunteers
- 539 people
- Sponsor
- University of Washington
HIV-1-infection
Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine
The current study proposal is an open label observational trial for maintenance of virologic suppression, and is designed as a non- inferiority switch trial.
- Trial name
- NCT04538040
- Testing
- Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Quest Clinical Research
Chronic Hepatitis B
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.
- Trial name
- NCT02579382
- Testing
- TDF, Vesatolimod
- Where
- 21 sites in United States, Canada and 6 more
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Hepatitis C, HIV Coinfection
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
This study will evaluate the effect of ledipasvir/sofosbuvir (LDV/SOF) treatment on the pharmacokinetics (PK) and renal safety of tenofovir in the form of tenofovir alafenamide (TAF).
- Trial name
- NCT03126370
- Testing
- TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
HIV-1 Infection
Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years
The primary objective of this study is to evaluate the safety of elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone…
- Trial name
- NCT02616783
- Testing
- E/C/F/TAF, TDF, FTC
- Where
- 35 sites in Belgium, France and 3 more
- Volunteers
- 167 people
- Sponsor
- Gilead Sciences
HIV-1
A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human…
- Trial name
- NCT03227861
- Testing
- DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- Where
- 16 sites in United States
- Volunteers
- 109 people
- Sponsor
- Janssen Scientific Affairs, LLC
Hepatitis B
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Chronic HBV patients will receive 9 doses of open-label ARC-520 once every 4 weeks and be evaluated for safety and efficacy.
- Trial name
- NCT02738008
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 6 sites in China, Germany and 1 more
- Volunteers
- 12 people
- Sponsor
- Arrowhead Pharmaceuticals
Human Immunodeficiency Virus
Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
A 48-week, open label, non comparative prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for more than 24 weeks (human immunodeficiency virus-1 RNA…
- Trial name
- NCT02652793
- Testing
- Boosted atazanavir, Lamivudine
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Judit Pich
HIV-1 Infection
Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
The primary objective of the study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) after switching from a stable regimen consisting of…
- Trial name
- NCT02616029
- Testing
- E/C/F/TAF
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Hepatitis B
Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B
This study will test whether the combination of two medications, tenofovir and emtricitabine, are safer and more effective for treating chronic hepatitis B than tenofovir alone.
- Trial name
- NCT00524173
- Testing
- Tenofovir & Emtricitabine, Tenofovir
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV Infection
Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART
This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of adolescents and young adults with HIV infection in the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) who are…
- Trial name
- NCT01751646
- Testing
- Vitamin D3 50,000 IU
- Where
- 17 sites in United States, Puerto Rico
- Volunteers
- 214 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV-1 Infection
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir
This study was done with people who were infected with HIV, but did not show any signs of having HIV. They were also feeling well without taking HIV medication and had low or undetectable levels of the virus in the blood.
- Trial name
- NCT01777997
- Testing
- Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
- Where
- 19 sites in United States
- Volunteers
- 38 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen
The purpose of this study is to evaluate any change from baseline in bone mineral density (BMD) in subjects following the switch from a triple antiretroviral therapy (ART) regimen containing Tenofovir disoproxil fumarate (TDF) to…
- Trial name
- NCT02478632
- Testing
- Subjects do not receive study medication in this study 202094
- Where
- 32 sites in United States, Argentina and 4 more
- Volunteers
- 102 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC)…
- Trial name
- ASSURE (NCT01102972)
- Testing
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 297 people
- Sponsor
- ViiV Healthcare
Hiv
Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study
Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.
- Trial name
- DORAVIPEP (NCT04233372)
- Testing
- Delstrigo
- Where
- 2 sites in France, Spain
- Volunteers
- 399 people
- Sponsor
- Hospital Clinic of Barcelona
HIV I Infection
Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF
Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
- Trial name
- DYAD (NCT04585737)
- Testing
- Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Charlotte-Paige Rolle, MD
HIV-1, Central Nervous System
Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)
This study aims to evaluate a switch from fixed dose combination (FDC) treatment with ATRIPLA^TM for 12 weeks prior to screening to FDC treatment with Doravirine, Tenofovir, Lamivudine (MK-1439A) in virologically-suppressed…
- Trial name
- NCT02652260
- Testing
- Doravirine, Tenofovir, Lamivudine - Blinded, Doravirine, Tenofovir, Lamivudine - Open-Label, ATRIPLA^TM
- Volunteers
- 86 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV
Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
The purpose of this study is to assess the effectiveness of an implementation model which integrates tenofovir gel provision into existing family planning services.
- Trial name
- NCT01691768
- Testing
- 1% tenofovir gel
- Where
- 2 sites in South Africa
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Centre for the AIDS Programme of Research in South Africa